United-Guardian (UG) Q1 2026 earnings summary

Executive summary

• Net sales rose 16% year-over-year in Q1 2026 to $2,872,222, driven by strong pharmaceutical and cosmetic ingredient sales, notably Renacidin and increased purchases by Ashland Specialty Ingredients.

• Net income increased 46% to $818,902, with EPS up to $0.18 from $0.12.

• New distribution agreement for sexual wellness products signed, with anticipated growth in that segment.

• Strategic focus on expanding Renacidin’s formulary coverage and increasing healthcare professional outreach.

• Settlement income from a contract manufacturer contributed to quarterly income following a facility shutdown in late 2023.

Financial highlights

• Net sales: $2,872,222 in Q1 2026 vs. $2,481,127 in Q1 2025 (up 16%).

• Net income: $818,902 in Q1 2026 vs. $560,895 in Q1 2025 (up 46%).

• EPS (basic/diluted): $0.18 in Q1 2026 vs. $0.12 in Q1 2025.

• Gross margin: 50% in Q1 2026, down from 55% in Q1 2025 due to higher pharmaceutical sales mix.

• Total other income surged to $390,689 from $97,037, including $303,133 in settlement income.

Outlook and guidance

• Positioned for growth in sexual wellness and personal care segments, with new products ready for launch.

• Continued investment in product development and market expansion, especially for Renacidin.

• Optimism for continued sales growth in 2026, supported by resumed distributor purchasing, new distribution agreements, and expanded product lines.